What is gamma-delta-beta-thalassemia?

Gamma-delta-beta-thalassemia is an extremely rare complex form of beta-thalassemia caused by deletions that impair production of gamma, delta and beta chains or coordinated activation of the corresponding genes within the beta-globin cluster.

Which genes are involved in γδβ-thalassemia?

Deletions may involve the gamma-globin genes HBG2 and HBG1, the delta-globin gene HBD and the beta-globin gene HBB. Some variants instead involve the locus control region, reducing expression of globin genes even when their structure is preserved.

What is the difference between γδβ-thalassemia and εγδβ-thalassemia?

In γδβ-thalassemia, the defect includes the gamma, delta and beta chains or their regulatory regions. When the deletion also involves the epsilon gene HBE1 and abolishes expression of the entire beta-like cluster, the condition is more precisely defined as εγδβ-thalassemia.

How is gamma-delta-beta-thalassemia inherited?

The deletion is transmitted in an autosomal manner. Heterozygous carriers may also develop anemia during fetal or neonatal life, whereas later they may have only microcytosis and mild anemia.

What are the symptoms of γδβ-thalassemia?

Manifestations may include neonatal microcytic anemia, pallor, jaundice, hyperbilirubinemia and signs of hemolysis. After the neonatal period, microcytosis, hypochromia and mild anemia may persist, while severity varies among individual forms and depends on the molecular subtype and genetic modifiers.

Why can γδβ-thalassemia cause neonatal anemia?

During fetal and neonatal life, gamma chains are especially required. Their reduced production from the affected allele creates an imbalance between alpha and non-alpha chains, with ineffective erythropoiesis, red-cell instability and hemolysis.

Can neonatal anemia improve with growth?

Yes. In many heterozygous carriers, anemia improves during the first months, when the physiologic switch from gamma-chain synthesis to beta-chain synthesis allows the unaffected allele to support hemoglobin production to a greater extent.

How is gamma-delta-beta-thalassemia diagnosed?

Diagnosis integrates the complete blood count, reticulocyte count, peripheral smear, hemolysis markers and analysis of hemoglobin fractions. Confirmation requires molecular techniques capable of identifying large deletions or regulatory defects of the beta-globin cluster.

Which genetic techniques identify γδβ-thalassemia?

The most useful techniques include MLPA, genomic microarray, long-range PCR and targeted sequencing or NGS. Family studies make it possible to define the extent of the deletion and its inheritance pattern.

What does hemoglobin electrophoresis show?

The profile depends on the genes and regulatory regions involved. Variations in HbF, HbA2 and HbA may be present, but there is no single diagnostic pattern that applies to all γδβ deletions.

Does gamma-delta-beta-thalassemia require transfusions?

Mild forms require no treatment. Transfusions may be necessary during the neonatal period or in forms associated with severe anemia, but in carriers the requirement may decrease as the hematologic picture improves spontaneously.

How is γδβ-thalassemia treated?

Treatment is individualized and may include hematologic monitoring, neonatal care, transfusions in symptomatic cases and monitoring for iron overload in patients receiving repeated transfusions.

What complications can it cause?

Severe forms may cause severe neonatal anemia, hyperbilirubinemia, a need for transfusion and cardiopulmonary complications secondary to anemia. Repeated transfusions may lead to iron accumulation.

What is the prognosis of gamma-delta-beta-thalassemia?

Prognosis depends mainly on the clinical phenotype, molecular subtype and genetic modifiers, with marked variability even among similar genotypes. In heterozygous carriers, the picture often improves after the neonatal period and may evolve toward mild microcytosis; biallelic forms or forms associated with other hemoglobinopathies may be more severe.

Why is genetic counseling important?

Genetic counseling makes it possible to define the familial deletion, distinguish γδβ-thalassemia from other complex thalassemias and assess the risk of transmitting clinically more severe combinations.

L'angolo del dottorino

Change Language:

Index

Search the site... Advanced search

✖

Gamma-Delta-Beta-Thalassemia

Article written and reviewed by Dr Luca Moretti

Gamma-delta-beta-thalassemia (γδβ-thalassemia) is an extremely rare condition caused by deletions or rearrangements of the beta-globin cluster involving the gamma, delta and beta genes or their respective regulatory regions. The classic families described in the literature are heterozygous: the normal allele remains active and the phenotype changes with development.

Etiology, Genetics and Pathophysiology

On the affected allele, the deletion reduces or abolishes synthesis of gamma, delta and beta globins. During fetal and neonatal life, loss of gamma-chain production may cause significant anemia because the normal allele does not always meet demand. With the switch toward beta-chain synthesis during the first months of life, the condition often tends to improve. Functional hemoglobin production is not lost globally because the other allele continues to produce beta-like chains.

Clinical Manifestations

Neonatal hemolytic anemia, jaundice and, in more marked cases, a need for transfusion have been documented. The subsequent course may show rapid improvement, leaving mild microcytic, hypochromic anemia or minimal findings in adulthood. Severity depends on the molecular subtype, breakpoints, residual regulation and genetic modifiers, without a monotonic relationship with deletion size; a progressive homozygous phenotype, massive bone expansion or chronic transfusion dependence should not be described as typical.

Diagnosis and Investigations

Suspicion arises from unexplained neonatal anemia, familial microcytosis or an atypical hemoglobin profile. After the neonatal period, HbA, HbA2 and HbF may be present and even close to usual values, so electrophoresis and HPLC do not exclude the deletion. Confirmation requires copy-number and breakpoint analysis of the beta-globin cluster, for example by MLPA, genomic array or targeted molecular methods, together with family studies.

Treatment and Prognosis

Treatment is supportive during the neonatal period and includes transfusions when clinically necessary and management of jaundice or cardiocirculatory instability. Regular transfusions or splenectomy are not indicated in patients who improve spontaneously. Prognosis after the neonatal period is often favorable in isolated heterozygous forms, but it must be defined according to the specific deletion and the clinical data of the affected family.

Complications

The main complications involve fetal and neonatal life: severe anemia, hyperbilirubinemia, heart failure and possible adverse perinatal events. Iron overload is not a typical feature of the isolated heterozygous form and mainly concerns patients who receive repeated transfusions. The chronic complications typical of transfusion-dependent thalassemias are not characteristic of the isolated heterozygous form.

References

Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. Blackwell Science. 4th ed. 2001.
Forget BG, Bunn HF. Classification of the disorders of hemoglobin. Cold Spring Harb Perspect Med. 2013;3(2):a011684.
Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. Cambridge University Press. 2nd ed. 2009.
Bain BJ. Haemoglobinopathy Diagnosis. Wiley-Blackwell. 3rd ed. 2020.
Oort M, Heerspink W, Roos D, Flavell RA, Bernini LF. Haemolytic disease of the newborn and chronic anaemia induced by gamma-beta thalassaemia in a Dutch family. Br J Haematol. 1981;48(2):251–262.
Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379(9813):373–383.
Bain BJ, Daniel Y, Henthorn J, de la Salle B, Hogan A, Roy NBA, et al.; British Society for Haematology. Significant haemoglobinopathies: A guideline for screening and diagnosis. Br J Haematol. 2023;201(6):1047-1065.
Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med. 2013;3(5):a011700.
Old JM. Haemoglobinopathies and thalassaemias. Medicine. 2020;48(8):511–519.
Kattamis A, Kwiatkowski JL, Aydinok Y. Thalassaemia. Lancet. 2022;399(10343):2310-2324.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.